Search PubMed⌕ Search

Biomedical subjects

E Radzikowska

Publications and source records attributed to E Radzikowska.

45 records · Page 3Linked to original sources
PubMed1994

[Familial aggregation of lung cancer in families of patients with lung cancer].

For determination of whether lung cancer clusters in families, an analysis was conducted on morbidity-mortality data, occupational and tobacco use practices for family members of 189 lung cancer probands and 211 controls (patients without cancer admitted to hospital because of accidents). Significant increase (1.48) was observed in cancers of all anatomic sites among relatives of lung cancer patients. Overall male relatives of lung cancer patients had 9.5 and female 11.8 greater risk for lung cancer than relatives of controls. This results remained significant after adjusting for age and smoking.

Adenocarcinoma↗
PubMed1994

[Analysis of prognostic factors for long term survival in patients with small cell lung cancer].

Prognostic factors for long term survival were analyzed in a group of 719 patients with small cell lung carcinoma treated within 4 consecutive prospective multicenter trials between 1981 and 1990. 74 patients (10.3%) survived more than 2 years; 30 of them (4.2%) with no evidence of disease. The most significant determinator of prolonged survival was extent of disease: 13.9% (59/424) of patients with limited disease vs. 5.1% (15/295) with extensive disease survived more than 2 years (p < 0.001). Of 138 female patients 24 (17.4%) were long term survivors, compared to 8.6% (50/581) of males (p < 0.01). Initial good performance status and no weight loss were also found to be correlated with long term survival. Of the group of 2-year survivors 51 patients subsequently died (median survival duration 31 months), 10 are alive with cancer or are lost to follow up and 13 are in complete remission with median follow up of 64 months. 20 patients (3.8%) survived more than 5 years. This study confirms the possibility of cure in SCLC, especially in patients with favorable prognostic factors.

Adult↗
PubMed1993

[Antipyrine metabolism in lung cancer patients].

In order to assess the activity of enzymatic metabolism of oncogenic benzo (a) pyrenes the half life of antipyrine was calculated in 60 lung cancer patients and 75 healthy volunteers without known familial malignancy. It was found that antipyrine activity was significantly higher in lung cancer patients than in healthy volunteers, after taking in account sex, age and smoking habits. Antipyrine half life was significantly higher in adenocarcinoma in comparison with other types of cancer. Metabolism of antipyrine was also higher in advanced cases of lung cancer. A relation between higher metabolism and lower age onset of lung cancer was not demonstrated.

Adenocarcinoma↗
PubMedDate not supplied

Lung cancer in patients under 50 years old.

PURPOSE: The community based lung cancer registry was set up and the results were analysed to assess the differences in clinicopathological parameters and survival between patients under and over 50 years of age. PATIENTS AND METHODS: The Pulmonary Outpatient Clinics supplied the data on 5404 lung cancer patients diagnosed in Poland in 1995. Data regarding demographic, smoking, histology, clinical stage, performance status, family history of cancer, therapy and survival were obtained. RESULTS: At time of diagnosis 757 (14%) patients were under 50 years of age. In this group the frequency of females was higher as compared to this in the group of older patients (24.2% vs. 12.1%; P<0.001). Also the incidence of adenocarcinoma (12.6% vs. 7.6%; P<0.001) and small cell lung cancer (22.9% vs. 14.8%; P<0.001) were significantly higher in younger patients. Young patients had better performance status (55.4% vs. 46.6%; P<0.001) than old. The incidence of cancer in families of younger patients was higher both among the mothers (4.7% vs. 3.0%; P<0.001) and among the fathers (7.6% vs. 4.1%, P<0.001). Surgery or chemotherapy were more often applied to patients under 50 years in comparison to older ones (P<0.001). Young patients had better prognosis. Higher percentage of them survived one year (32.6% vs. 28.9%; P<0.049). In multivariate analysis, age over 50 at diagnosis, male gender, diagnosis of small cell lung cancer, advanced stage of the disease, bad performance status, and non-surgical therapy were independent negative prognostic factors. CONCLUSION: Among young patients, overrepresentation of women, subjects with positive family history of cancer, with better performance status, with adenocarcinoma and small cell lung cancer were noticed. Young patients were treated more aggressively and had better prognosis than patients over 50 years of age.

Adenocarcinoma↗